Compare
Shoulder Innovations, Inc. vs TriSalus Life Sciences, Inc. vs Carlsmed, Inc. vs SANUWAVE Health, Inc.
| Latest fiscal year | Shoulder Innovations, Inc. SI | TriSalus Life Sciences, Inc. TLSI | Carlsmed, Inc. CARL | SANUWAVE Health, Inc. SNWV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $47.32M | $45.15M | $50.51M | $44.05M |
| Revenue growth (YoY) | +49.6% | +53.4% | +85.9% | +35.0% |
| Gross margin | 76.5% | 84.6% | 75.3% | 77.1% (computed) |
| Operating margin | -55.6% | -59.7% | -60.5% | 11.2% |
| Net margin | -85.3% | -86.9% | -58.7% | 26.8% |
| Net income | -$40.36M | -$39.23M | -$29.63M | $11.81M |
| EPS (Diluted) | -$4.65 | -$1.84 | -$2.12 | $0.41 |
| Operating cash flow | -$28.61M | -$18.01M | -$28.98M | $3.88M |
| Free cash flow | -$36.02M | -$18.93M | -$29.62M | $1.93M |
| Cash & equivalents | $26.87M | $20.44M | $85.79M | $11.96M |
| Total assets | $169.91M | $35.33M | $130.12M | $37.34M |
| Total liabilities | $29.16M | $69.19M | $31.25M | $35.72M |
| Shareholders' equity | $140.75M | -$33.86M | $98.87M | $1.62M |
| Return on year-end equity | -28.7% | n/a | -30.0% | 729.6% |
| Shares outstanding | 20.62M | 50.00M | 26.60M | 8.59M |
Revenue, most recent five fiscal years
| Fiscal year | Shoulder Innovations, Inc. | TriSalus Life Sciences, Inc. | Carlsmed, Inc. | SANUWAVE Health, Inc. |
|---|---|---|---|---|
| Latest | $47.32M Ended 2025-12-31 | $45.15M Ended 2025-12-31 | $50.51M Ended 2025-12-31 | $44.05M Ended 2025-12-31 |
| 1 year earlier | $31.62M Ended 2024-12-31 | $29.43M Ended 2024-12-31 | $27.16M Ended 2024-12-31 | $32.63M Ended 2024-12-31 |
| 2 years earlier | n/a | $18.51M Ended 2023-12-31 | n/a | $20.40M Ended 2023-12-31 |
| 3 years earlier | n/a | $12.40M Ended 2022-12-31 | n/a | $16.74M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $13.01M Ended 2021-12-31 |